Literature DB >> 17936155

Altered intestinal function in patients with chronic heart failure.

Anja Sandek1, Juergen Bauditz, Alexander Swidsinski, Sabine Buhner, Jutta Weber-Eibel, Stephan von Haehling, Wieland Schroedl, Tim Karhausen, Wolfram Doehner, Mathias Rauchhaus, Philip Poole-Wilson, Hans-Dieter Volk, Herbert Lochs, Stefan D Anker.   

Abstract

OBJECTIVES: We evaluated morphology and function of the gut in patients with chronic heart failure (CHF).
BACKGROUND: Intestinal translocation of bacterial endotoxin may contribute to the inflammatory state observed in patients with CHF. The morphology and function of the gut may be abnormal.
METHODS: We studied 22 patients with CHF (age 67 +/- 2 years, left ventricular ejection fraction [LVEF] 31 +/- 1%, New York Heart Association functional class 2.3 +/- 0.1, peak VO2 15.0 +/- 1.0 ml/kg/min) and 22 control subjects (62 +/- 1 years, LVEF 68 +/- 2%, peak VO2 24.7 +/- 1.3 ml/kg/min). Bowel wall thickness was assessed by transcutaneous sonography, small intestinal permeability by the lactulose-mannitol test, passive carrier-mediated transport by D-xylose test, large intestinal permeability by sucralose test (5- and 26-h urine collection, high-performance liquid chromatography), and mucosal bacterial biofilm by fluorescence in situ hybridization in biopsies taken during sigmoidoscopy.
RESULTS: Chronic heart failure patients, compared with control patients, showed increased bowel wall thickness in the terminal ileum (1.48 +/- 0.16 mm vs. 1.04 +/- 0.08 mm), ascending colon (2.32 +/- 0.18 mm vs. 1.31 +/- 0.14 mm), transverse colon (2.19 +/- 0.20 vs. 1.27 +/- 0.08 mm), descending colon (2.59 +/- 0.18 mm vs. 1.43 +/- 0.13 mm), and sigmoid (2.97 +/- 0.27 mm vs. 1.64 +/- 0.14 mm) (all p < 0.01). Chronic heart failure patients had a 35% increase of small intestinal permeability (lactulose/mannitol ratio: 0.023 +/- 0.001 vs. 0.017 +/- 0.001, p = 0.006), a 210% increase of large intestinal permeability (sucralose excretion: 0.62 +/- 0.17% vs. 0.20 +/- 0.06%, p = 0.03), and a 29% decrease of D-xylose absorption, indicating bowel ischemia (26.7 +/- 3.0% vs. 37.4 +/- 1.4%, p = 0.003). Higher concentrations of adherent bacteria were found within mucus of CHF patients compared with control subjects (p = 0.007).
CONCLUSIONS: Chronic heart failure is a multisystem disorder in which intestinal morphology, permeability, and absorption are modified. Increased intestinal permeability and an augmented bacterial biofilm may contribute to the origin of both chronic inflammation and malnutrition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17936155     DOI: 10.1016/j.jacc.2007.07.016

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  151 in total

1.  Evaluation of Innate Immunity Biomarkers on Admission and at Discharge From an Acute Heart Failure Episode.

Authors:  Nuno Silva; Emília Patrício; Paulo Bettencourt; João Tiago Guimarães
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

Review 2.  From obesity through gut microbiota to cardiovascular diseases: a dangerous journey.

Authors:  Paolo Marzullo; Laura Di Renzo; Gabriella Pugliese; Martina De Siena; Luigi Barrea; Giovanna Muscogiuri; Annamaria Colao; Silvia Savastano
Journal:  Int J Obes Suppl       Date:  2020-07-20

3.  Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial).

Authors:  Tetz C Lee; Min Qian; Gregory Y H Lip; Marco R Di Tullio; Susan Graham; Douglas L Mann; Koki Nakanishi; John R Teerlink; Ronald S Freudenberger; Ralph L Sacco; J P Mohr; Arthur J Labovitz; Piotr Ponikowski; Dirk J Lok; Conrado Estol; Stefan D Anker; Patrick M Pullicino; Richard Buchsbaum; Bruce Levin; John L P Thompson; Shunichi Homma; Siqin Ye
Journal:  Am J Cardiol       Date:  2018-06-04       Impact factor: 2.778

4.  Increased Small Intestinal Permeability during Severe Acute Exacerbations of COPD.

Authors:  Roy T M Sprooten; Kaatje Lenaerts; Dionne C W Braeken; Ilvy Grimbergen; Erica P Rutten; Emiel F M Wouters; Gernot G U Rohde
Journal:  Respiration       Date:  2018-01-25       Impact factor: 3.580

Review 5.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

Review 6.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Veli-Pekka Harjola; Wilfried Mullens; Marek Banaszewski; Johann Bauersachs; Hans-Peter Brunner-La Rocca; Ovidiu Chioncel; Sean P Collins; Wolfram Doehner; Gerasimos S Filippatos; Andreas J Flammer; Valentin Fuhrmann; Mitja Lainscak; Johan Lassus; Matthieu Legrand; Josep Masip; Christian Mueller; Zoltán Papp; John Parissis; Elke Platz; Alain Rudiger; Frank Ruschitzka; Andreas Schäfer; Petar M Seferovic; Hadi Skouri; Mehmet Birhan Yilmaz; Alexandre Mebazaa
Journal:  Eur J Heart Fail       Date:  2017-05-30       Impact factor: 15.534

Review 7.  Phosphate imbalance in patients with heart failure.

Authors:  E C Christopoulou; T D Filippatos; E Megapanou; M S Elisaf; G Liamis
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 8.  Resuscitation-induced intestinal edema and related dysfunction: state of the science.

Authors:  Shinil K Shah; Karen S Uray; Randolph H Stewart; Glen A Laine; Charles S Cox
Journal:  J Surg Res       Date:  2009-09-29       Impact factor: 2.192

9.  Effects of timing, sex, and age on site-specific gastrointestinal permeability testing in children and adults.

Authors:  Mark E McOmber; Ching-Nan Ou; Robert J Shulman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-03       Impact factor: 2.839

Review 10.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.